TFX Earnings Prediction
The chart below shows how TFX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, TFX sees a +2.04% change in stock price 10 days leading up to the earnings, and a -0.02% change 10 days following the report. On the earnings day itself, the stock moves by -2.80%. This data can give you a slight idea of what to expect for the next quarter's release.
TFX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
764.38M
2.41%
1.96%
Gross Margin
0.00%
--
-100.00%
Operating Margin
0.00%
--
-100.00%
Net Margin
0.00%
--
-100.00%
EPS
0.00
-18.62%
-100.00%
No Data Available
TFX Earnings Analysis
Teleflex Incorporated Corporation (TFX.N) Earnings Conference Call
Positive
Quarterly Revenue Increase: 1. Revenue Growth: Teleflex reported third quarter revenues of $764.4 million, reflecting a 2.4% year-over-year increase on a GAAP basis and a 2.2% increase on an adjusted constant currency basis.
Vascular Access Revenue Growth: 2. Strong Vascular Access Performance: Revenue from Vascular Access increased by 6.3% year-over-year to $180.9 million, driven by strong demand for peripheral and central access products.
Interventional Revenue Increase: 3. Interventional Revenue Surge: The Interventional segment saw a significant revenue increase of 11.4% year-over-year, totaling $149.9 million, indicating robust performance across the product portfolio.
Gross Margin Improvement: 4. Improved Gross Margin: The adjusted gross margin for the quarter was 60.8%, a 140 basis point increase compared to the prior year, primarily due to favorable pricing and the termination of the MSA.
Cash Flow Improvement: 5. Increased Cash Flow: Cash flow from operations for the first nine months of 2024 was $435.6 million, up $63.2 million from the prior year, demonstrating strong operational efficiency and cash generation.
Negative
Revenue Shortfall: 1. Revenue Miss: Teleflex reported third quarter revenues of $764.4 million, slightly below the guidance range of $765 million to $770 million, indicating unanticipated softness in the OEM business.
Other Revenue Decline: 2. Decline in Other Revenue: Other revenue declined by 28.3% year-over-year to $54.8 million, primarily due to the planned exit of the MSA by Medline.
Earnings Per Share Decline: 3. Decreased Earnings Per Share: Adjusted earnings per share for the third quarter was $3.49, reflecting a 4.1% decrease year-over-year, impacted by dilution from the acquisition of Palette Life Sciences and a higher tax rate.
OEM Revenue Decline: 4. OEM Revenue Softness: OEM revenue increased only 0.1% year-over-year to $82.6 million, with a significant loss of revenue due to a large customer deciding to vertically integrate a component previously supplied by Teleflex, resulting in a $14 million impact on full-year guidance.
Revised Revenue Forecast: 5. Lowered Revenue Guidance: The updated 2024 revenue guidance was revised down to a growth range of 3.5% to 4%, compared to the previous range of 4.25% to 5.25%, reflecting lower-than-anticipated revenue in both the OEM and Interventional Urology businesses.
TFX FAQs
How does TFX typically perform around its earnings report dates?
Is Teleflex Incorporated (TFX) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
TFX Earning Call Sentiment
Teleflex Incorporated (TFX) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
TFX.N
-0.09%Positive
The earnings call summary reflects strong financial performance, with revenue and margin growth. The strategic initiatives, such as the acquisition of Palette Life Sciences and the share repurchase program, are likely to have positive impacts. Despite some concerns about OEM pressures and UroLift weakness, the overall guidance is optimistic, with raised revenue and EPS forecasts. The Q&A section did not reveal significant negative sentiment from analysts. Given these factors, the stock is expected to have a positive movement in the next two weeks.
